Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Techniques in Coloproctology
Erschienen in: Techniques in Coloproctology 1/2019

30.01.2019 | Review

Colorectal cancer in inflammatory bowel disease: review of the evidence

verfasst von: D. S. Keller, A. Windsor, R. Cohen, M. Chand

Erschienen in: Techniques in Coloproctology | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Inflammatory bowel disease (IBD)-related colorectal cancer (CRC) is responsible for approximately 2% of the annual mortality from CRC overall, but 10–15% of the annual deaths in IBD patients. IBD-related CRC patients are also affected at a younger age than sporadic CRC patients, and have a 5-year survival rate of 50%. Despite optimal medical treatment, the chronic inflammatory state inherent in IBD increases the risk for high-grade dysplasia and CRC, with additional input from genetic and environmental risk factors and the microbiome. Recognizing risk factors, implementing appropriate surveillance, and identifying high-risk patients are key to managing the CRC risk in IBD patients. Chemoprevention strategies exist, and studies evaluating their efficacy are underway. Once dysplasia or invasive cancer is diagnosed, appropriate surgical resection and postoperative treatment and surveillance are necessary. Here, we discuss the current state of IBD-related CRC, prevalence, risk factors, and evidence for surveillance, prophylaxis, and treatment recommendations.
Literatur
1.
Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–E386PubMed
2.
Bradley CJ, Lansdorp-Vogelaar I, Yabroff KR et al (2011) Productivity savings from colorectal cancer prevention and control strategies. Am J Prev Med 41:e5–e14CrossRefPubMedPubMedCentral
3.
Burisch J, Jess T, Martinato M, Lakatos PL, ECCO E (2013) The burden of inflammatory bowel disease in Europe. J Crohns Colitis 7:322–337CrossRefPubMed
4.
Loftus EVJ (2004) Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 126:1504–1517CrossRefPubMed
5.
Gheorghe C, Pascu O, Gheorghe L et al (2004) Epidemiology of inflammatory bowel disease in adults who refer to gastroenterology care in Romania: a multicentre study. Eur J Gastroenterol Hepatol 16:1153–1159CrossRefPubMed
6.
Mattar MC, Lough D, Pishvaian MJ, Charabaty A (2011) Current management of inflammatory bowel disease and colorectal cancer. Gastrointest Cancer Res 4:53–61PubMedPubMedCentral
7.
Ekbom A, Helmick C, Zack M, Adami HO (1990) Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 323:1228–1233CrossRefPubMed
8.
Brackmann S, Andersen SN, Aamodt G et al (2009) Two distinct groups of colorectal cancer in inflammatory bowel disease. Inflamm Bowel Dis 15:9–16CrossRefPubMed
9.
Bernstein CN, Blanchard JF, Kliewer E, Wajda A (2001) Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 91:854–862CrossRefPubMed
10.
11.
Mellemkjaer L, Olsen JH, Frisch M, Johansen C, Gridley G, McLaughlin JK (1995) Cancer in patients with ulcerative colitis. Int J Cancer 60:330–333CrossRefPubMed
12.
von Roon AC, Reese G, Teare J, Constantinides V, Darzi AW, Tekkis PP (2007) The risk of cancer in patients with Crohn’s disease. Dis Colon Rectum 50:839–855CrossRef
13.
Canavan C, Abrams KR, Mayberry J (2006) Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn’s disease. Aliment Pharmacol Ther 23:1097–1104CrossRefPubMed
14.
Jess T, Simonsen J, Jørgensen KT, Pedersen BV, Nielsen NM, Frisch M. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology. 2012;143:375.e1–381.e1 (quiz e13) CrossRef
15.
Jess T, Loftus EV, Velayos FS et al (2006) Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology 130:1039–1046CrossRefPubMed
16.
Kappelman MD, Farkas DK, Long MD et al. Risk of cancer in patients with inflammatory bowel diseases: a nationwide population-based cohort study with 30 years of follow-up evaluation. Clin Gastroenterol Hepatol. 2014;12:265.e1–273.e1
17.
Tsianos (2000) Risk of cancer in inflammatory bowel disease (IBD). Eur J Intern Med 11:75–78CrossRefPubMed
18.
Lutgens MW, van Oijen MG, van der Heijden GJ, Vleggaar FP, Siersema PD, Oldenburg B (2013) Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis 19:789–799CrossRefPubMed
19.
Fornaro R, Caratto M, Caratto E et al (2016) Colorectal cancer in patients with inflammatory bowel disease: the need for a real surveillance program. Clin Colorectal Cancer 15:204–212CrossRefPubMed
20.
Rutter MD, Saunders BP, Wilkinson KH et al (2006) Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 130:1030–1038CrossRefPubMed
21.
Ullman T, Odze R, Farraye FA (2009) Diagnosis and management of dysplasia in patients with ulcerative colitis and Crohn’s disease of the colon. Inflamm Bowel Dis 15:630–638CrossRefPubMed
22.
van den Heuvel TR, Wintjens DS, Jeuring SF et al (2016) Inflammatory bowel disease, cancer and medication: cancer risk in the Dutch population-based IBDSL cohort. Int J Cancer 139:1270–1280CrossRefPubMed
23.
Scaringi S, Di Martino C, Zambonin D et al (2013) Colorectal cancer and Crohn’s colitis: clinical implications from 313 surgical patients. World J Surg 37:902–910CrossRefPubMed
24.
Nuako KW, Ahlquist DA, Mahoney DW, Schaid DJ, Siems DM, Lindor NM (1998) Familial predisposition for colorectal cancer in chronic ulcerative colitis: a case–control study. Gastroenterology 115:1079–1083CrossRefPubMed
25.
Askling J, Dickman PW, Karlén P et al (2001) Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology 120:1356–1362CrossRefPubMed
26.
Sebastian S, Hernández V, Myrelid P et al (2014) Colorectal cancer in inflammatory bowel disease: results of the 3rd ECCO pathogenesis scientific workshop (I). J Crohns Colitis 8:5–18CrossRefPubMed
27.
Feagins LA, Souza RF, Spechler SJ (2009) Carcinogenesis in IBD: potential targets for the prevention of colorectal cancer. Nat Rev Gastroenterol Hepatol 6:297–305CrossRefPubMed
28.
Itzkowitz SH, Yio X (2004) Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 287:G7–G17CrossRefPubMed
29.
Westbrook AM, Szakmary A, Schiestl RH (2010) Mechanisms of intestinal inflammation and development of associated cancers: lessons learned from mouse models. Mutat Res 705:40–59CrossRefPubMedPubMedCentral
30.
Goel GA, Kandiel A, Achkar JP, Lashner B (2011) Molecular pathways underlying IBD-associated colorectal neoplasia: therapeutic implications. Am J Gastroenterol 106:719–730CrossRefPubMed
31.
32.
Dirisina R, Katzman RB, Goretsky T et al (2011) p53 and PUMA independently regulate apoptosis of intestinal epithelial cells in patients and mice with colitis. Gastroenterology 141:1036–1045CrossRefPubMed
33.
Velayos FS, Loftus EV, Jess T et al (2006) Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case–control study. Gastroenterology 130:1941–1949CrossRefPubMed
34.
Bezzio C, Festa S, Saibeni S, Papi C (2017) Chemoprevention of colorectal cancer in ulcerative colitis: digging deep in current evidence. Expert Rev Gastroenterol Hepatol 11:339–347CrossRefPubMed
35.
Kang M, Martin A (2017) Microbiome and colorectal cancer: unraveling host-microbiota interactions in colitis-associated colorectal cancer development. Semin Immunol 32:3CrossRefPubMed
36.
Grivennikov SI (2013) Inflammation and colorectal cancer: colitis-associated neoplasia. Semin Immunopathol 35:229–244CrossRefPubMed
37.
McCoy AN, Araújo-Pérez F, Azcárate-Peril A, Yeh JJ, Sandler RS, Keku TO (2013) Fusobacterium is associated with colorectal adenomas. PLoS One 8:e53653CrossRefPubMedPubMedCentral
38.
Arthur JC, Perez-Chanona E, Mühlbauer M et al (2012) Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 338:120–123CrossRefPubMedPubMedCentral
39.
Khan AA, Khan Z, Malik A et al (2017) Colorectal cancer-inflammatory bowel disease nexus and felony of Escherichia coli. Life Sci 180:60CrossRefPubMed
40.
Cooper K, Squires H, Carroll C et al (2010) Chemoprevention of colorectal cancer: systematic review and economic evaluation. Health Technol Assess 14:1–206CrossRefPubMed
41.
Johnson CC, Jankowski M, Rolnick S, Yood MU, Alford SH (2014) Influence of NSAID use among colorectal cancer survivors on cancer outcomes. Am J Clin Oncol
42.
Haggar FA, Boushey RP (2009) Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg 22:191–197CrossRefPubMedPubMedCentral
43.
Ullman TA, Itzkowitz SH (2011) Intestinal inflammation and cancer. Gastroenterology 140:1807–1816CrossRefPubMed
44.
Pinczowski D, Ekbom A, Baron J, Yuen J, Adami HO (1994) Risk factors for colorectal cancer in patients with ulcerative colitis: a case–control study. Gastroenterology 107:117–120CrossRefPubMed
45.
Qiu X, Ma J, Wang K, Zhang H (2017) Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis. Oncotarget 8:1031–1045PubMed
46.
OʼConnor A, Packey CD, Akbari M, Moss AC (2015) Mesalamine, but Not sulfasalazine, reduces the risk of colorectal neoplasia in patients with inflammatory bowel disease: an agent-specific systematic review and meta-analysis. Inflamm Bowel Dis 21:2562–2569CrossRefPubMed
47.
Chapman CG, Rubin DT (2014) The potential for medical therapy to reduce the risk of colorectal cancer and optimize surveillance in inflammatory bowel disease. Gastrointest Endosc Clin N Am 24:353–365CrossRefPubMedPubMedCentral
48.
Poutahidis T, Haigis KM, Rao VP et al (2007) Rapid reversal of interleukin-6-dependent epithelial invasion in a mouse model of microbially induced colon carcinoma. Carcinogenesis 28:2614–2623CrossRefPubMed
49.
Kim YJ, Hong KS, Chung JW, Kim JH, Hahm KB (2010) Prevention of colitis-associated carcinogenesis with infliximab. Cancer Prev Res (Phila) 3:1314–1333CrossRef
50.
Bassaganya-Riera J, Viladomiu M, Pedragosa M, De Simone C, Hontecillas R (2012) Immunoregulatory mechanisms underlying prevention of colitis-associated colorectal cancer by probiotic bacteria. PLoS One 7:e34676CrossRefPubMedPubMedCentral
51.
Neumann H, Vieth M, Langner C, Neurath MF, Mudter J (2011) Cancer risk in IBD: how to diagnose and how to manage DALM and ALM. World J Gastroenterol 17:3184–3191CrossRefPubMedPubMedCentral
52.
Guagnozzi D, Lucendo AJ (2012) Colorectal cancer surveillance in patients with inflammatory bowel disease: what is new. World J Gastrointest Endosc 4:108–116CrossRefPubMedPubMedCentral
53.
Annese V, Daperno M, Rutter MD et al (2013) European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis 7:982–1018CrossRefPubMed
54.
Rex DK, Boland CR, Dominitz JA et al (2017) Colorectal cancer screening: recommendations for physicians and patients from the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 153:307–323CrossRefPubMed
55.
Cairns SR, Scholefield JH, Steele RJ et al (2010) Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 59:666–689CrossRefPubMed
56.
Abraham BP (2016) Cancer surveillance in ulcerative colitis and Crohn’s disease: new strategies. Curr Opin Gastroenterol 32:32–37CrossRefPubMed
57.
Kiesslich R, Goetz M, Lammersdorf K et al (2007) Chromoscopy-guided endomicroscopy increases the diagnostic yield of intraepithelial neoplasia in ulcerative colitis. Gastroenterology 132:874–882CrossRefPubMed
58.
Gabbani T, Manetti N, Bonanomi AG, Annese AL, Annese V (2015) New endoscopic imaging techniques in surveillance of inflammatory bowel disease. World J Gastrointest Endosc 7:230–236CrossRefPubMedPubMedCentral
59.
Cheon JH (2015) Advances in the endoscopic assessment of inflammatory bowel diseases: cooperation between endoscopic and pathologic evaluations. J Pathol Transl Med 49:209–217CrossRefPubMedPubMedCentral
60.
Lashner BA, Kane SV, Hanauer SB (1990) Colon cancer surveillance in chronic ulcerative colitis: historical cohort study. Am J Gastroenterol 85:1083–1087PubMed
61.
Karlén P, Kornfeld D, Broström O, Löfberg R, Persson PG, Ekbom A (1998) Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis? A population based case control study. Gut 42:711–714CrossRefPubMedPubMedCentral
62.
Lutgens MW, Oldenburg B, Siersema PD et al (2009) Colonoscopic surveillance improves survival after colorectal cancer diagnosis in inflammatory bowel disease. Br J Cancer 101:1671–1675CrossRefPubMedPubMedCentral
63.
Bye WA, Nguyen TM, Parker CE, Jairath V, East JE (2017) Strategies for detecting colon cancer in patients with inflammatory bowel disease. Cochrane Database Syst Rev 9:CD000279PubMed
64.
Eaden JA, Ward BA, Mayberry JF (2000) How gastroenterologists screen for colonic cancer in ulcerative colitis: an analysis of performance. Gastrointest Endosc 51:123–128CrossRefPubMed
65.
van Rijn AF, Fockens P, Siersema PD, Oldenburg B (2009) Adherence to surveillance guidelines for dysplasia and colorectal carcinoma in ulcerative and Crohn’s colitis patients in the Netherlands. World J Gastroenterol 15:226–230CrossRefPubMedPubMedCentral
66.
Feuerstein JD, Lewandowski JJ, Martinez-Vazquez M, Leffler DA, Cheifetz AS (2015) Documented compliance with inflammatory bowel disease quality measures is poor. Dig Dis Sci 60:339–344CrossRefPubMed
67.
Mayer R, Wong WD, Rothenberger DA, Goldberg SM, Madoff RD (1999) Colorectal cancer in inflammatory bowel disease: a continuing problem. Dis Colon Rectum 42:343–347CrossRefPubMed
68.
Brackmann S, Andersen SN, Aamodt G et al (2009) Relationship between clinical parameters and the colitis-colorectal cancer interval in a cohort of patients with colorectal cancer in inflammatory bowel disease. Scand J Gastroenterol 44:46–55CrossRefPubMed
69.
Ullman TA (2003) Patients with low-grade dysplasia should be advised to undergo colectomy. Inflamm Bowel Dis 9:267–269 (discussion 273) CrossRefPubMed
70.
Bach JF (2002) The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 347:911–920CrossRefPubMed
71.
DeRoche TC, Xiao SY, Liu X (2014) Histological evaluation in ulcerative colitis. Gastroenterol Rep (Oxf) 2:178–192CrossRef
72.
Engelsgjerd M, Farraye FA, Odze RD (1999) Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis. Gastroenterology 117:1288–1294; (discussion 1488) CrossRefPubMed
73.
Odze RD, Farraye FA, Hecht JL, Hornick JL (2004) Long-term follow-up after polypectomy treatment for adenoma-like dysplastic lesions in ulcerative colitis. Clin Gastroenterol Hepatol 2:534–541CrossRefPubMed
74.
Rutter MD, Saunders BP, Wilkinson KH, Kamm MA, Williams CB, Forbes A (2004) Most dysplasia in ulcerative colitis is visible at colonoscopy. Gastrointest Endosc 60:334–339CrossRefPubMed
75.
Connell WR, Lennard-Jones JE, Williams CB, Talbot IC, Price AB, Wilkinson KH (1994) Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology 107:934–944CrossRefPubMed
76.
Jess T, Loftus EV, Velayos FS et al (2006) Incidence and prognosis of colorectal dysplasia in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota. Inflamm Bowel Dis 12:669–676CrossRefPubMed
77.
Thomas T, Nair P, Dronfield MW, Mayberry JF (2005) Management of low and high-grade dysplasia in inflammatory bowel disease: the gastroenterologists’ perspective and current practice in the United Kingdom. Eur J Gastroenterol Hepatol 17:1317–1324CrossRefPubMed
78.
Althumairi AA, Lazarev MG, Gearhart SL (2016) Inflammatory bowel disease associated neoplasia: a surgeon’s perspective. World J Gastroenterol 22:961–973CrossRefPubMedPubMedCentral
79.
Reynolds IS, O’Toole A, Deasy J, McNamara DA, Burke JP (2017) A meta-analysis of the clinicopathological characteristics and survival outcomes of inflammatory bowel disease associated colorectal cancer. Int J Colorectal Dis 32:443–451CrossRefPubMed
80.
Ou B, Zhao J, Guan S, Lu A (2016) Survival of colorectal cancer in patients with or without inflammatory bowel disease: a meta-analysis. Dig Dis Sci 61:881–889CrossRefPubMed
81.
Larsen M, Mose H, Gislum M et al (2007) Survival after colorectal cancer in patients with Crohn’s disease: a nationwide population-based Danish follow-up study. Am J Gastroenterol 102:163–167CrossRefPubMed
82.
Panis Y (1998) Is there a place for ileal pouch-anal anastomosis in patients with Crohn’s colitis. Neth J Med 53:S47–S51CrossRefPubMed
83.
Ramsey M, Krishna SG, Stanich PP et al (2017) Inflammatory bowel disease adversely impacts colorectal cancer surgery short-term outcomes and health-care resource utilization. Clin Transl Gastroenterol 8:e127CrossRefPubMedPubMedCentral
84.
Coviello LC, Stein SL (2014) Surgical management of nonpolypoid colorectal lesions and strictures in colonic inflammatory bowel disease. Gastrointest Endosc Clin N Am 24:447–454CrossRefPubMed
85.
Svrcek M, Cosnes J, Beaugerie L et al (2007) Colorectal neoplasia in Crohn’s colitis: a retrospective comparative study with ulcerative colitis. Histopathology 50:574–583CrossRefPubMed
86.
Deutsch AA, McLeod RS, Cullen J, Cohen Z (1991) Results of the pelvic-pouch procedure in patients with Crohn’s disease. Dis Colon Rectum 34:475–477CrossRefPubMed
87.
Keighley MR (2000) The final diagnosis in pouch patients for presumed ulcerative colitis may change to Crohn’s disease: patients should be warned of the consequences. Acta Chir Iugosl 47:27–31PubMed
88.
Melton GB, Fazio VW, Kiran RP et al (2008) Long-term outcomes with ileal pouch-anal anastomosis and Crohn’s disease: pouch retention and implications of delayed diagnosis. Ann Surg 248:608–616PubMed
89.
Tekkis PP, Heriot AG, Smith O, Smith JJ, Windsor AC, Nicholls RJ (2005) Long-term outcomes of restorative proctocolectomy for Crohn’s disease and indeterminate colitis. Colorectal Dis 7:218–223CrossRefPubMed
90.
Lightner AL, Fletcher JG, Pemberton JH, Mathis KL, Raffals LE, Smyrk T (2017) Crohn’s disease of the pouch: a true diagnosis or an oversubscribed diagnosis of exclusion. Dis Colon Rectum 60:1201–1208CrossRefPubMed
91.
Panis Y, Poupard B, Nemeth J, Lavergne A, Hautefeuille P, Valleur P (1996) Ileal pouch/anal anastomosis for Crohn’s disease. Lancet 347:854–857CrossRefPubMed
92.
Gentilini L, Coscia M, Laureti S, Poggioli G (2011) Surgery in presence of dysplasia in IBD. Ann Ital Chir 82:37–40PubMed
93.
Liu X, Goldblum JR, Zhao Z et al (2012) Distinct clinicohistologic features of inflammatory bowel disease-associated colorectal adenocarcinoma: in comparison with sporadic microsatellite-stable and Lynch syndrome-related colorectal adenocarcinoma. Am J Surg Pathol 36:1228–1233CrossRefPubMed
94.
Tiersten A, Saltz LB (1996) Influence of inflammatory bowel disease on the ability of patients to tolerate systemic fluorouracil-based chemotherapy. J Clin Oncol 14:2043–2046CrossRefPubMed
95.
Dugum M, Lin J, Lopez R et al (2017) Recurrence and survival rates of inflammatory bowel disease-associated colorectal cancer following postoperative chemotherapy: a comparative study. Gastroenterol Rep (Oxf) 5:57–61
96.
Axelrad J, Kriplani A, Ozbek U et al (2017) Chemotherapy tolerance and oncologic outcomes in patients with colorectal cancer with and without inflammatory bowel disease. Clin Colorectal Cancer 16:e205–e210CrossRefPubMed
97.
Renz BW, Thasler WE, Preissler G et al (2013) Clinical outcome of IBD-associated versus sporadic colorectal cancer: a matched-pair analysis. J Gastrointest Surg 17:981–990CrossRefPubMed
98.
Hrabe JE, Byrn JC, Button AM, Zamba GK, Kapadia MR, Mezhir JJ (2014) A matched case–control study of IBD-associated colorectal cancer: IBD portends worse outcome. J Surg Oncol 109:117–121CrossRefPubMed
99.
Kim BJ, Yang SK, Kim JS et al (2009) Trends of ulcerative colitis-associated colorectal cancer in Korea: a KASID study. J Gastroenterol Hepatol 24:667–671CrossRefPubMed
100.
Kim AH, Roberts C, Feagan BG et al (2017) Developing a standard set of patient-centred outcomes for inflammatory bowel disease—an international, cross-disciplinary consensus. J Crohns Colitis 12:408CrossRef
101.
Annese V, Beaugerie L, Egan L et al (2015) European evidence-based consensus: inflammatory bowel disease and malignancies. J Crohns Colitis 9:945–965CrossRefPubMed
Metadaten
Titel
Colorectal cancer in inflammatory bowel disease: review of the evidence
verfasst von
D. S. Keller
A. Windsor
R. Cohen
M. Chand
Publikationsdatum
30.01.2019
Verlag
Springer International Publishing
Erschienen in
Techniques in Coloproctology / Ausgabe 1/2019
Print ISSN: 1123-6337
Elektronische ISSN: 1128-045X
DOI
https://doi.org/10.1007/s10151-019-1926-2

Weitere Artikel der Ausgabe 1/2019

Techniques in Coloproctology 1/2019 Zur Ausgabe

Review

Meta-analysis of the effect of perioperative intravenous lidocaine on return of gastrointestinal function after colorectal surgery

Video Forum

Distal purse-string suture technique for TaTME

Original Article

A validated severity score for haemorrhoids as an essential prerequisite for future haemorrhoid trials

The Last Image

Pyoderma gangrenosum as first manifestation of Crohn’s disease

Trick of the Trade

Minimal open hemorrhoidectomy

Editorial

In search of the optimal operation for rectal prolapse: the saga continues…

Neu im Fachgebiet Chirurgie

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Operationsvorbereitung | Nachrichten

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Ureterstriktur: Innovative OP-Technik bewährt sich
weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.